FDA Adverse Event Malfunction Summary report: N

INVISALIGN ALIGNER

MDR report key: 19995566 · Received August 14, 2024

Report

Report Number
MW5158470
Event Type
Malfunction
Date Received
August 14, 2024
Date of Event
June 30, 2023
Report Date
August 11, 2024
Manufacturer
ALIGN TECHNOLOGY, INC.
Product Code
NXC
Product Problem
Yes
Report Source
Voluntary report
Reporter Location
CA, US
Reporter Occupation
PATIENT
Health Professional
*

Narratives

Description of Event or Problem · 0

CONSUMER COMPLAINT AGAINST INVISALIGN I AM AN INVISALIGN USER. I AM ALSO AN EXECUTIVE WITH A MEDICAL DEVICE COMPANY. I HAVE HELD EXECUTIVE-LEVEL MARKETING, SALES, AND STRATEGY ROLES AT COMPANIES SUCH AS ABBOTT, EDWARDS, AND TERUMO. I BELIEVE INVISALIGN IS ENGAGED IN FALSE AND MISLEADING CONSUMER CLAIMS AND ADVERTISING. I ALSO BELIEVE THE COMPANY'S EFFICACY DATA IS INCONSISTENT WITH FDA STANDARDS. A BYPRODUCT, I THINK, OF THE COMPANY MAKING INVISALIGN PRODUCTS AVAILABLE TO GENERAL DENTISTS WHO LACK THE TECHNICAL TRAINING TO CLINICAL ADVICE TREATMENT. I STARTED MY INVISALIGN JOURNEY IN 2022. UPON THE INITIAL SCAN OF MY TEETH, I WAS TOLD I WOULD NEED TO WEAR THE "RETAINERS" FOR 16 WEEKS. OVER 1.5 YEARS PAST AND I WAS STILL GETTING WHAT THE COMPANY CALLS "REFINEMENTS." I WAS RELIGIOUS ABOUT WEARING THE PRODUCTS. NOW, TWO YEARS OUT (AND AFTER WEARING THE NIGHTTIME RETAINERS DAILY) MY TEETH ARE NEARLY BACK TO THE PRE-ALIGNER STATE. I BELIEVE THE COMPANY KNOWS THAT THEY "BAIT AND SWITCH" USERS INTO THINKING THAT THE EXPERIENCE WILL BE SHORT AND SWEET. BUT AS I SPOKE TO THE STAFF AT MY DENTIST OFFICE, I AM TOLD THIS IS A NORMAL DYNAMIC. THE COMPANY SAYS "X WEEKS,' AND THE REALITY IS MORE LIKE "X TO THE THIRD OR FOURTH POWER." YES, IT WAS NOT A GOOD USE OF MY $(B)(6). BUT MORE THAN THAT, I THINK THE COMPANY MUST KNOW THAT Y% OF THEIR CUSTOMERS EXPERIENCE THE INITIAL PROGNOSIS. I ALSO BELIEVE THERE IS SOMETHING UNLAWFUL ABOUT THE MODEL. I MADE THE MISTAKE OF GOING TO MY LOCAL DENTIST, WITH HIS PROUD "SILVER LEVEL INVISALIGN IMPLANTER" PLAQUE PROMINENTLY DISPLAYED (BY THE WAY, THIS IS A MARKET-DEVELOPMENT/BUSINESS-DEVELOPMENT TOOL, NOT A PATIENT EDUCATION ELEMENT AND SOMETHING THE FDA SHOULD LEAN-IN ON). HE OFFERED ZERO TECHNICAL GUIDANCE. AND THAT MEANS THAT THE PRESCRIPTION OF THE PRODUCT ITSELF IS REMOTE AND SOFTWARE-BASED. THEY SCAN, SEND THE DATA TO A PROGRAM THAT REALLY DOESN'T WORK, AND THE LOCAL, LIGHTLY TRAINED DENTIST SIMPLY INPUTS DATA. THE DENTIST IS THERE TO PLACE/GLUE ANCHORS. THAT IS IT. I SUSPECT THE EXPERIENCE IS VERY DIFFERENT IN AN ORTHODONTIST OFFICE WHERE THERE IS MORE CLINICAL DEPTH. I AM CERTAIN THAT THE BUSINESS MODEL DRIVES A LOT OF REPEAT BUSINESS BECAUSE THE RESULTS TO NOT LAST. I COME FROM THE WORLD OF HEART VALVES, TAVR, AND MITRACLIP WHERE POOR EFFICACY RESULTS IN PATIENT DEATHS. I ASK THE FDA TO INVESTIGATE INVISALIGN ACROSS THREE AREAS: 1. FALSE AND MISLEADING CLAIMS RELATING TO THE INITIAL/ESTIMATED PATIENT JOURNEY (CONVENIENCE, COST, ETC.) 2. FALSE AND MISLEADING CLAIMS REGARDING CLINICAL DURABILITY 3. EXTENDING THE CLINICAL GUIDANCE TOO FAR (GENERAL DENTISTRY VS. ORTHODONTICS).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2350671 INVISALIGN ALIGNER ALIGNER, SEQUENTIAL NXC ALIGN TECHNOLOGY, INC.

Patients

Seq Age Sex Outcome Treatment
1 56 YR Male Other ADVAIR.